MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin

Zhan,Ce; Li,Cheng; Zhang,Hao; Tang,Hao; Ji,Fang; Qiao,Su‑Chi; Xu,Wei‑Dong; Wang,Zhi‑Wei

doi:10.3892/ol.2016.5046

MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin

Authors:
- Ce Zhan
- Cheng Li
- Hao Zhang
- Hao Tang
- Fang Ji
- Su‑Chi Qiao
- Wei‑Dong Xu
- Zhi‑Wei Wang
View Affiliations

Affiliations: Department of Orthopedics, Changhai Hospital, The Second Military Medical University, Shanghai 200433, P.R. China
Published online on: August 25, 2016 https://doi.org/10.3892/ol.2016.5046
Pages: 3457-3462

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effect of microRNA-150 (miRNA/miR‑150) in osteosarcoma (OS) cell invasion and metastasis by the regulation of Ezrin. To compare the differences in the expression of miR‑150 and Ezrin, cell models of OS metastasis were established by exogenous transfection of miR‑150 on the basis of different expression levels of miR‑150. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to estimate these expression levels. Ezrin expression was detected by western blot assay. Methylthiazolyldiphenyl‑tetrazolium bromide assay was performed to determine cells proliferation. Cell invasion and migration were measured in vitro by Transwell migration assays. Detection of apoptosis adopted flow cytometry. The results of RT‑qPCR showed that the miR‑150 expression in OS F5M2 cells was significantly increased following exogenous transfection of miR‑150 mimics, and the expression of miR‑150 was positively correlated with the concentration of the miR‑150 mimics. Western blot assay indicated that the Ezrin expression in the F5M2 cells was decreased with the exogenous overexpression of miR‑150. Additionally, Transwell assays revealed that the overexpression of miR‑150 significantly suppressed the invasion and metastasis ability of the F5M2 cells. miR‑150 upregulation may reduce OS cell invasion and metastasis by downregulating the expression of Ezrin.

View Figures

View References

1	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
2	Tang N, Song WX, Luo J, Haydon RC and He TC: Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res. 466:2114–2130. 2008. View Article : Google Scholar : PubMed/NCBI
3	Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: State of the art. Cancer Metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
4	Broadhead ML, Clark JC, Myers DE, Dass CR and Choong PF: The molecular pathogenesis of osteosarcoma: A review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
5	Ritter J and Bielack SS: Osteosarcoma. Ann Oncol. 21(Suppl 7): vii320–vii325. 2010.PubMed/NCBI
6	Corradi D, Wenger DE, Bertoni F, Bacchini P, Bosio S, Goldoni M, Unni KK, Sim FH and Inwards CY: Multicentric osteosarcoma: Clinicopathologic and radiographic study of 56 cases. Am J Clin Pathol. 136:799–807. 2011. View Article : Google Scholar : PubMed/NCBI
7	Lussier DM, O'Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P and Blattman JN: Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother. 38:96–106. 2015. View Article : Google Scholar : PubMed/NCBI
8	Gorlick R: Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 152:467–478. 2009. View Article : Google Scholar : PubMed/NCBI
9	Mirabello L, Pfeiffer R, Murphy G, Daw NC, Patiño-Garcia A, Troisi RJ, Hoover RN, Douglass C, Schüz J, Craft AW and Savage SA: Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control. 22:899–908. 2011. View Article : Google Scholar : PubMed/NCBI
10	Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J and Randall RL: miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
11	O'Connell RM, Rao DS and Baltimore D: microRNA regulation of inflammatory responses. Annu Rev Immunol. 30:295–312. 2012. View Article : Google Scholar : PubMed/NCBI
12	Reid G, Kirschner MB and van Zandwijk N: Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 80:193–208. 2011. View Article : Google Scholar : PubMed/NCBI
13	Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K, Ren G, Su T, Pan Y, Feng B, et al: MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
14	Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, et al: Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 117:3140–3146. 2011. View Article : Google Scholar : PubMed/NCBI
15	Turchinovich A, Weiz L, Langheinz A and Burwinkel B: Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39:7223–7233. 2011. View Article : Google Scholar : PubMed/NCBI
16	McDermott AM, Heneghan HM, Miller N and Kerin MJ: The therapeutic potential of microRNAs: Disease modulators and drug targets. Pharm Res. 28:3016–3029. 2011. View Article : Google Scholar : PubMed/NCBI
17	Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell. 148:1172–1187. 2012. View Article : Google Scholar : PubMed/NCBI
18	Olson EN: MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med. 6:239ps32014. View Article : Google Scholar : PubMed/NCBI
19	Zhou X, Wei M and Wang W: MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1. Biochem Biophys Res Commun. 437:653–658. 2013. View Article : Google Scholar : PubMed/NCBI
20	Bao YP, Yi Y, Peng LL, Fang J, Liu KB, Li WZ and Luo HS: Roles of microRNA-206 in osteosarcoma pathogenesis and progression. Asian Pac J Cancer Prev. 14:3751–3755. 2013. View Article : Google Scholar : PubMed/NCBI
21	Jacob NK, Cooley JV, Yee TN, Jacob J, Alder H, Wickramasinghe P, Maclean KH and Chakravarti A: Identification of sensitive serum microRNA biomarkers for radiation biodosimetry. PLoS One. 8:e576032013. View Article : Google Scholar : PubMed/NCBI
22	Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X, et al: Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 39:133–144. 2010. View Article : Google Scholar : PubMed/NCBI
23	Bezman NA, Chakraborty T, Bender T and Lanier LL: miR-150 regulates the development of NK and iNKT cells. J Exp Med. 208:2717–2731. 2011. View Article : Google Scholar : PubMed/NCBI
24	Zhang N, Wei X and Xu L: miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett. 587:2346–2351. 2013. View Article : Google Scholar : PubMed/NCBI
25	Park HR, Jung WW, Bacchini P, Bertoni F, Kim YW and Park YK: Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract. 202:509–515. 2006. View Article : Google Scholar : PubMed/NCBI
26	Hunter KW: Ezrin, a key component in tumor metastasis. Trends Mol Med. 10:201–204. 2004. View Article : Google Scholar : PubMed/NCBI
27	Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 10:182–186. 2004. View Article : Google Scholar : PubMed/NCBI
28	Watanabe A, Tagawa H, Yamashita J, Teshima K, Nara M, Iwamoto K, Kume M, Kameoka Y, Takahashi N, Nakagawa T, et al: The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia. 25:1324–1334. 2011. View Article : Google Scholar : PubMed/NCBI
29	Yokobori T, Suzuki S, Tanaka N, Inose T, Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H and Kuwano H: MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 104:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
30	Miao J, Wu S, Peng Z, Tania M and Zhang C: MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects. Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
31	Cai H, Lin L, Cai H, Tang M and Wang Z: Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol. 30:4992013. View Article : Google Scholar : PubMed/NCBI
32	Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X and Fan Q: miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med. 30:1013–1020. 2012.PubMed/NCBI
33	Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X and Wang L: Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 180:2440–2451. 2012. View Article : Google Scholar : PubMed/NCBI
34	Neisch AL and Fehon RG: Ezrin, radixin and moesin: Key regulators of membrane-cortex interactions and signaling. Curr Opin Cell Biol. 23:377–382. 2011. View Article : Google Scholar : PubMed/NCBI
35	Clark JC, Dass CR and Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
36	Kafchinski LA and Jones KB: MicroRNAs in osteosarcomagenesis. Adv Exp Med Biol. 804:119–127. 2014. View Article : Google Scholar : PubMed/NCBI